Merck Initiates Its ENHANCE-3 Phase 3 Randomized Clinical Trial Evaluating OHTUVAYRE For The Prevention Of Chronic Obstructive Pulmonary Disease
Key takeaways
- Merck launches a large global trial to prove OHTUVAYRE can reduce COPD flare‑ups, aiming to cement its place as a key maintenance therapy.
- 2,136 patients
- 28 countries
- June 2024 FDA approval
What happened
Merck has started the ENHANCE‑3 Phase 3 trial, enrolling about 2,136 patients in 28 countries to test OHTUVAYRE (ensifentrine) for preventing COPD exacerbations.
Why it matters
The study will provide the largest evidence base yet for OHTUVAYRE, a drug that combines bronchodilation with anti‑inflammatory action and was approved in June 2024. Positive results could solidify its role as a first‑line maintenance therapy for COPD and expand its use beyond the current market.
Short-term and longer-term
Short-term. Merck’s stock may see short‑term volatility as the trial begins, with traders watching enrollment milestones and early safety signals.
Longer-term. For investors, the trial’s outcome could reshape Merck’s COPD portfolio, potentially increasing long‑term revenue streams.
Words on this card
- COPD
- Chronic obstructive pulmonary disease, a progressive lung condition causing breathing difficulties
- Exacerbation
- A worsening of COPD symptoms that often requires additional treatment
- Bronchodilator
- A drug that relaxes airway muscles to improve breathing
- Anti‑inflammatory
- A medication that reduces inflammation in the lungs
- FDA
- U.S. Food and Drug Administration, the agency that approves drugs